Get the Stockscreener App
94.23
0.04%
-0.04
Pre-market:
93.90
-0.33
-0.35%
Boston Scientific Corp stock is traded at $94.23, with a volume of 6.46M.
It is down -0.04% in the last 24 hours and down -3.02% over the past month.
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
See More
Previous Close:
$94.27
Open:
$94.66
24h Volume:
6.46M
Relative Volume:
0.83
Market Cap:
$139.37B
Revenue:
$16.75B
Net Income/Loss:
$1.85B
P/E Ratio:
75.38
EPS:
1.25
Net Cash Flow:
$2.37B
1W Performance:
+3.96%
1M Performance:
-3.02%
6M Performance:
+8.60%
1Y Performance:
+39.72%
1-Day Range:
$93.69
$95.12
1-Week Range:
$86.77
$97.65
52-Week Range:
$66.80
$107.17
Boston Scientific Corp Stock (BSX) Company Profile
Name
Boston Scientific Corp
Sector
Industry
Phone
508-683-4000
Address
300 BOSTON SCIENTIFIC WAY, MARLBOROUGH, MA
Compare BSX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BSX
Boston Scientific Corp
|
94.23 | 139.37B | 16.75B | 1.85B | 2.37B | 1.25 |
|
ABT
Abbott Laboratories
|
126.22 | 218.91B | 41.95B | 13.40B | 6.35B | 7.65 |
|
SYK
Stryker Corp
|
346.80 | 132.37B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
82.37 | 105.64B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
70.76 | 41.45B | 5.72B | 4.17B | 259.90M | 6.97 |
Boston Scientific Corp Stock (BSX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Oct-18-24 | Downgrade | Needham | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Feb-01-24 | Upgrade | Mizuho | Neutral → Buy |
| Jul-19-23 | Initiated | Robert W. Baird | Outperform |
| Jun-30-23 | Initiated | CL King | Buy |
| May-30-23 | Resumed | Morgan Stanley | Overweight |
| Mar-29-23 | Initiated | UBS | Buy |
| Dec-22-22 | Initiated | Mizuho | Neutral |
| Dec-20-22 | Resumed | Citigroup | Buy |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Jul-06-22 | Initiated | Wolfe Research | Outperform |
| May-27-22 | Upgrade | Needham | Hold → Buy |
| Apr-13-22 | Resumed | Truist | Buy |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| May-26-21 | Downgrade | Needham | Buy → Hold |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Overweight |
| Sep-17-20 | Initiated | Truist | Buy |
| Sep-11-20 | Initiated | Wolfe Research | Peer Perform |
| Apr-22-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Apr-01-20 | Upgrade | Goldman | Neutral → Buy |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Buy |
| Dec-30-19 | Reiterated | Cowen | Outperform |
| Dec-19-19 | Downgrade | Needham | Strong Buy → Buy |
| Sep-05-19 | Resumed | JP Morgan | Overweight |
| Sep-03-19 | Resumed | Barclays | Overweight |
| May-13-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Nov-28-18 | Initiated | UBS | Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Oct-02-18 | Reiterated | Morgan Stanley | Overweight |
| Sep-07-18 | Reiterated | Needham | Strong Buy |
| Sep-04-18 | Upgrade | Jefferies | Hold → Buy |
| Jul-06-18 | Reiterated | Needham | Strong Buy |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Apr-26-18 | Reiterated | Needham | Strong Buy |
View All
Boston Scientific Corp Stock (BSX) Latest News
Boston Scientific Corporation (BSX): A Bull Case Theory - Yahoo Finance
RBC Capital maintains Outperform on Boston Scientific, $116 target - Investing.com
Smart Pills Market Detailed In New Research Report 2025 | Boston - openPR.com
A Look At The Fair Value Of Boston Scientific Corporation (NYSE:BSX) - Yahoo Finance
Truist Lowers Price Target for Boston Scientific (BSX) Ahead of Q1 Results | BSX Stock News - GuruFocus
Boston Scientific (BSX) Ascends But Remains Behind Market: Some Facts to Note - Yahoo Finance
Boston Scientific price target lowered to $113 from $120 at Truist - TipRanks
Is Boston Scientific Gaining or Losing Market Support? - Benzinga
Boston Scientific (BSX) Is Considered a Good Investment by Brokers: Is That True? - Yahoo Finance
Boston Scientific (BSX) Surges 6.8%: Is This an Indication of Further Gains? - Yahoo Finance
FDA clears path for Boston Sci’s Bolt IVL to challenge J&J’s Shockwave - BioWorld MedTech
Lobbying Update: $20,000 of BOSTON SCIENTIFIC CORPORATION lobbying was just disclosed - Nasdaq
What to Expect From Boston Scientific’s Q1 2025 Earnings Report - Nasdaq
Boston Scientific (NYSE:BSX) Announces Robust Q4 Results With Increased Sales And Net Income - Yahoo Finance
Interventional Neurology Market Deep Research 2025-2032 | - openPR.com
What To Expect From Boston Scientific’s Q1 2025 Earnings Report - Barchart.com
PFA non-inferior, even superior, to cryoablation for paroxysmal AF - BioWorld MedTech
Boston Scientific Insiders Sell US$1.8m Of Stock, Possibly Signalling Caution - Yahoo Finance
Trump Tariffs Spare Drugmakers But Threaten Diabetes Device Industry - Benzinga
Health Rounds: Some early breast cancers may not need surgery after chemo - MarketScreener
Boston Scientific (BSX) Stock Moves -1.55%: What You Should Know - Yahoo Finance
Tariffs on medical devices could raise healthcare costs - The Business Journals
Boston Scientific Sued Over Endoscopic Medical Device Patent - Bloomberg Law News
Boston Scientific (BSX) Faces Pressure from New Tariffs - GuruFocus
Stryker, Boston Scientific down as new tariffs impact medtech industry - Seeking Alpha
Price Over Earnings Overview: Boston Scientific - Benzinga
Here's Why Boston Scientific (BSX) is a Strong Growth Stock - Yahoo Finance
Is Boston Scientific (NYSE:BSX) A Risky Investment? - Yahoo Finance
Boston Scientific’s Farapulse matches Medtronic cryoablation in trial - Yahoo Finance
Boston Scientific CEO Michael Mahoney sells $16.4 million in stock By Investing.com - Investing.com South Africa
No benefit found for cerebral protection device in TAVR - BioWorld MedTech
Boston Scientific CEO Michael Mahoney sells $16.4 million in stock - Investing.com India
Boston Scientific closes Bolt Medical acquisition - MassDevice
Evercore ISI Adjusts Boston Scientific Price Target to $110 From $112, Maintains Outperform Rating - MarketScreener
Boston Scientific Co. (NYSE:BSX) Shares Purchased by Groupama Asset Managment - MarketBeat
Boston Scientific announces conference call discussing first quarter 2025 results - Quantisnow
FDA Approval Boosts Boston Scientific's (BSX) Investment in Bolt Medical - GuruFocus
FDA clears Bolt Medical’s IVL system, backing Boston Scientific’s $664m buyout - Yahoo Home
Boston Scientific (BSX): Among the Best Healthcare Stocks to Buy According to Billionaires - Insider Monkey
Boston Scientific Corp (BSX-N) Stock Price and News - The Globe and Mail
Boston Scientific Sets Q1 Earnings Date: CEO and CFO to Detail 2025 Performance - Stock Titan
Boston Scientific (BSX) Exceeds Market Returns: Some Facts to Consider - Yahoo Finance
FDA clears Boston Scientific Bolt IVL system - MassDevice
Boston Scientific Farapulse PFA system shows superiority in head-to-head study with Medtronic cryoablation system - MassDevice
Boston Scientific Co. (NYSE:BSX) is Homestead Advisers Corp's 8th Largest Position - MarketBeat
Boston Scientific Corporation (NYSE:BSX) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead ? - Yahoo Finance
Boston Scientific to acquire SoniVie - Today's Medical Developments
$100 Invested In Boston Scientific 5 Years Ago Would Be Worth This Much Today - Benzinga
International Expansion, Product Launches Support BSX Stock - Yahoo Finance
Goldman Sachs Adjusts Price Target on Boston Scientific to $116 From $119, Maintains Buy Rating - Marketscreener.com
The Zacks Analyst Blog Highlights Tesla, The Home Depot, Boston Scientific, Frequency Electronics and Bridger Aerospace - Yahoo Finance
Boston Scientific Corp Stock (BSX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.87%
1.27%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):